General information on COVID-19 vaccines
Over the last two years, the COVID-19 pandemic has challenged societies and healthcare systems worldwide. In response, vaccines and therapeautic treatments have been rapidly developed. To date (October 2022), the European Medicines Agency (EMA) has approved six vaccines against COVID-19:
- Comirnaty - produced by Pfizer/BioNTech, approved on 21st December 2020. New updates variants for boosters are available (Oct 2022), for example, Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5
- Spikevax - produced by Moderna, approved on 6th January 2021. New updated variant for boosters is available (Oct 2022), Spikevax bivalent Original/Omicron BA.1.
- Vaxzevria (previously called COVID-19 Vaccine AstraZeneca) - produced by AstraZeneca, approved on 29th January 2021.
- Jcovden (previously COVID-19 Vaccine Janssen) - produced by Janssen, approved on 11th March 2021.
- Nuvaxovid - produced by Novavax, approved on 20th December 2021.
- COVID-19 Vaccine Valneva - produced by Valneva Austria GmbH, approved on 24th June 2022.
New vaccines are developed regularly, and are reviewed by EMA. Please refer to EMA’s page on COVID-19 vaccines to see the latest information on which vaccine are approved, which have submitted marketing authorisation, and which are under rolling review. New vaccines remain under rolling review until EMA have reviewed clinical trial data and determined that there is sufficient evidence to enable developers to apply for marketing authorisation.
As of October 2022, only Comirnaty (Pfizer/BioNTech), Spikevax (Moderna), and Nuvaxovid (Novavax) are available in Sweden. Vaxzevria (AstraZeneca) was used in past, but ceased to be used after 1st September 2021. The latest information on which vaccines are currently in use in Sweden can be found in emergency information from Swedish authorities.
COVID-19 vaccination in Sweden
On this page, we explore publicly available data for COVID-19 vaccination in Sweden. We visualise multiple different aspects of vaccine coverage (i.e. the amount of people that have received a vaccination). Specifically, we consider coverage on different spatial scales (including Sweden in general, as well as specific counties), in different age groups, and for different dose levels. We provide links to the data underlying the visualisations and the scripts used to produce them. The visualisations do not include information about the type of vaccine used.
This page also displays information about ongoing research projects across Sweden related to COVID-19 vaccines. The list includes different kinds of projects, including life science projects, registry-based projects, and public health projects. We also display a subset of publications related to vaccine research by researchers affiliated with a Swedish university or research institute.
For more information on vaccination in Sweden, please also see the RECOVAC dashboard on this portal. The dashboard contains information and data visualisations related to the register-based large-scale national population study to monitor COVID-19 vaccination effectiveness and safety (RECOVAC).
Visualisations related to vaccination coverage
The Swedish Health Agency (Folkhälsomyndigheten, FoHM) provide information, summary statistics, and data related to COVID-19 vaccination in Sweden (only available in Swedish). The visualisations below are based on the publicly available COVID-19 vaccination data from FoHM, which can be downloaded directly. For each visualisation, we describe which data in the dataset were used, how calculations were completed, and provide a link to the script(s) used to produce it.
The source data is updated weekly (on Thursdays), and the visualisations on this page will be updated shortly thereafter (usually on Fridays). All of our code related to this page is available on GitHub. All of the vaccine data is processed using a single data preparation script. The code required to generate each visualisation/number set is linked close to the corresponding plot/text.
General summary statistics
In this section, we examine the overall levels of vaccination in Sweden, as well as the recent rate of vaccination.
Vaccine coverage can be calculated in multiple ways. Below, we compare two methods used to determine the percentage of the Swedish population, in total, that have received at least X doses. One method, which we refer to as the ’eligible population method’, involves calculating the percentage of ’eligible’ individuals that have received at least a given number of doses. In Sweden, as in many countries, different age groups are eligible for different doses. As of October 2022, individuals born in or before 2010 (around 12 years old) are considered eligible for the first two doses, individuals born in or before 2004 (around 18 years old) are considered eligible for a booster, a third dose. The second booster, a fourth dose, is recommended for individuals over 65 years and risk groups over 18 years old, but also available for all individuals over 18 that wish to be vaccinated. Individuals born in or before 1957 (around 65 years old) are considered eligible for the fifth dose if at least four months has passed since the last dose. The other method of calculation for vaccine coverage, which we refer to as the ‘whole population method’, instead involves calculating the number of people vaccinated as a percentage of the entire population, regardless of how much of the population is eligible.
Please note, because not everyone is eligible for all doses, it would not be appropriate to compare values between the different dose levels for the purposes of asssessing e.g. vaccine coverage or uptake.
In the chart below, we show vaccine coverage as calculated using the ‘whole population’ and ’eligible population’ methods. The calculations consider the number of individuals in Sweden that have received at least 1, 2, 3, 4, or 5 doses. This is intended to highlight how the method of calculation used can influence reported measurements. As different methods are sometimes used by different countries, and by different organisations within a country, it is important to consider the method used before comparing data.
Please note, we refer to the number of doses administered (at least) for simplicity. However, other sources may use specific names/classifications to refer to different doses. For example, individuals given at least 2 doses may be considered ‘fully vaccinated’. The third dose is also sometimes referred to as a ‘booster dose’. Individuals with at least 3 doses are thus sometimes said to be ‘fully vaccinated with a booster dose’. Other variations also exist, and other terms may arise as subsequent doses becomes more widely available.
Vaccination data is spread between multiple tabs of the FoHM data file. For calculations done using the ’eligible population method’, we used percentage data from the ‘Vaccinerade tidsserie’, ‘Vaccinerade tidsserie dos 3’, ‘Vaccinerade tidsserie dos 4’, and ‘Vaccinerade tidsserie dos 5’ tabs of the FoHM data file. These tabs contained data about the amount of individuals that received at least one or two doses, at least 3 doses, at least 4 doses, and at least 5 doses, respectively. For the ‘whole population method’, we use the latest population data from Statistics Sweden (SCB) and the most recent ‘raw number’ of the doses administered from same tabs in the FoHM data file.
Note on the graph: Click on the coloured squares in the legend of the below graph to toggle which datasets are displayed. A single click will toggle just that dataset on/off. It is possible to display only one of the datasets by double-clicking on the desired dataset.
Code used to produce plot: Script to produce plot.
Code used to generate the ’live text’ in the summary paragraph below: ‘Live text’ script.
To summarise, in total, % of the population that are eligible for the first dose have received at least one dose of vaccination against COVID-19, which represents % of the whole population. The values indicate that % of the eligible population were vaccinated last week (a change in rate of % compared to the previous week), or % of the whole population (a change of % compared to the previous week). By contrast, % of those eligible, and % of the whole population have received at least two doses in total. The values indicate that % of those eligible and % of the whole population received their second dose last week (a change in rate of % and % compared to the previous week, respectively). In total, % of the eligible population received the third dose, representing % of the whole population. This means that % of the eligible population received their third dose last week (a change in rate of % compared to the previous week), or % of the whole population (a change of % compared to the previous week). To date, % of the whole population has received a fourth dose, and % of those eligible. In the last week, % of the whole population were vaccinated with a fourth dose, a change in rate of % compared to the previous week. By contast, % of the eligible population were vaccinated with a fourth dose, a relative change in rate of % compared to the previous week. A fifth dose was added in September 2022, % of the Swedish population have received that dose to date, which amounts to % of those eligible. A total of % of the whole population were vaccinated with a fifth dose in the last week, a change of % compared to the week before. When considering only the eligible population, % were given a fifth dose last week, which constitutes a relative change in rate of % compared to the previous week.
Administration of vaccinations over time
In Sweden, the first vaccine doses were administered in early 2021. As in other countries, the first two doses were made available to progressively younger age groups over time. The third dose of the vaccine was first offered in autumn of 2021, and was offered to individuals in particular ages groups at a given interval after their second dose. The age group and interval length differed over time, with age groups generally getting younger and the interval becoming shorter. A third dose is not offered to those under 18 years of age, unless there are additional considerations e.g. the individual is immunocompromised. In early 2022, a fourth dose was made available to those aged over 80, those receiving care, those living in housing facilities for the elderly, and those with severe immunodeficiency. This was extended to include those over 65 in April 2022. As of September 2022, it was made largely available to those over 18, though the availability varied between counties. At each stage of the rollout of the fourth dose, exceptions were made so that others could get the fourth dose under specific circumstances, for example, where an individual is immunocompromised or taking care of a vulnerable individual. A fifth dose was made available to those over 65 in September 2022 and, as with the other doses, it is likely to be made available to more of the population over time and other groups are able to access it under certain conditions.
Time series data is available in different tabs of the FoHM data file. We therefore took data from different places to produce the below time series. Time series data related to the amount of individuals that have received at least one or two doses is available in the ‘Vaccinerade tidsserie’ tab. Time series data about the amount of individuals that have at least 3, 4, or 5 doses is available in the ‘Vaccinerade tidsserie dos 3’, ‘Vaccinerade tidsserie dos 4’, and ‘Vaccinerade tidsserie dos 5’ tabs, respectively. Again, please note that it would not be appropriate to compare across all of the dose levels, both because the vaccines are not similarly available and because FoHM do not include all of the doses administered in their data. Firstly, a dose is only ‘counted’ in the FoHM data if it is administered to an individual within a specific age range. Data on the first on second doses is only included for individuals born in or before 2010 (around 12 years old). Data on the third and fourth doses is only included for individuals born in or before 2004 (around 18 years old). Data on the fifth dose is only included if it was given to an individual born in or before 1957 (around 65 years old). There are also some other caveats about whether a dose is ‘counted’ in the data file. In particular, data on the third dose is only included if it was registered after 1st September 2021 and at least 8 weeks after the individual received their second dose. Similarly, data on the fourth dose is only included if it was registered after 21st January 2022 and at least 8 weeks after the individual received their third dose. Lastly, data on dose 5 is only included if the dose was registerd after 15th August 2022 and was received at least 80 days after the individual received dose 4.
The below graph shows vaccine coverage across the whole of Sweden. We use the ‘whole population’ method for calculation, as this is more often used by other countries. Our calculations will therefore differ from the percentage values provided by FoHM as part of their summary statistics, because they use the ’eligible population’ method of calculation. For more details on the two methods, see the general summary statistics section.
Note on the graph: Click on the coloured squares in the legend of the below graph to toggle which datasets are displayed. A single click will toggle just that dataset on/off. It is possible to display only one of the datasets by double-clicking on the desired dataset.
Code used to produce plot: Script to produce plot.
Administration of vaccinations in each Swedish county (län)
In this section, we explore how many individuals in a given Swedish county (län) had at least X vaccine doses. Here, we again use the ‘whole population’ method of calculation (see the general summary statistics section for details). Data on the total number of people in each county was taken from Statistics Sweden (SCB). Data on the amount of individuals given at least one or two doses in each county was taken from the ‘Vaccinerade tidsserie’ tab of the data from FoHM. As mentioned in previous sections, only doses given to individuals born in or before 2010 (around 12 years old) are counted. Data on the amount of individuals given at least 3 or 4 doses (available in the ‘Vaccinerade tidsserie dos 3’ and ‘Vaccinerade tidsserie dos 4’ tabs of the FoHM data, respectively) is only given for those born bore 2004 (around 18 years old) and in accordance with specific timeframes and registration timepoints. Data on the fifth dose (available in the ‘Vaccinerade tidsserie dos 5’ tab of the FoHM data) is only available for those born before 1957 (around 65 years old), and in accordance with certain timeframes. Given the differences in which data is ‘counted’ for each dose, it is clear that data should not be compared across doses.
As data for the fifth dose is available to such a small amount of the population, we have decided to analyse the data using both the ‘whole population’ and ’eligible population’ methods. We feel that this will allow a clearer understanding of the differences between län in terms of the coverage for the fourth dose.
Again, please note that percentage values calculated using the ‘whole population method’ will differ from those calculated by FoHM, whose calculations do not consider the whole population, but rather the population eligible for the dose (from 12 years for the first and second doses, from 18 years for the third and fourth doses, and from 65 years for the fifth dose).
Received at least one vaccine dose
Code used to produce plot: Script to produce maps.
Received at least two vaccine doses
Code used to produce plot: Script to produce maps.
Received at least three vaccine doses
Code used to produce plot: Script to produce maps.
Received at least four vaccine doses
Code used to produce plot: Script to produce maps.
Received at least five vaccine doses
Please note the differences between the two below maps. Coverage appears to be very low when considering the whole population (left). However, coverage is higher when considering only the population eligible to receive the fifth dose (right). This difference occurs because, whilst a relatively small portion of the entire population is eligible to receive this dose, most of those eligible have received it.
Code used to produce plot: Script to produce maps.
Administration of vaccinations according to age group
The below heatmap provides some indication of the vaccine coverage across different age groups. The data for this heatmap differs from that in the previous visualisations. Specifically, instead of showing the number of people with ‘at least X doses’, the heatmap shows the number of people in Sweden in each age group that have been given that specific number of doses. For example, rather than showing the amount of people with ‘at least one dose’, we show the number that have had ‘only one dose’. Understandably, the number that have received ONLY one dose is relatively low across all age groups; individuals that have taken one dose are naturally more likely to take subsequent doses when they become eligible to do so. Given that individuals in more advanced age categories are eligible to take more doses, coverage is likely to be higher at a greater dose level. Age groups that have only recently become eligible for a given dose level are likely to initially show low coverage.
The fact that data is not available for each age category for every dose is reflected in the graph (a white colouration is used to indicate where data is not available/included). Data on the first three doses are available in the ‘Dos 1 till 3 per åldersgrupp’ tab of the FoHM dataset). Data on the fourth and fifth doses are instead available in the ‘Dos 4 18+’ and ‘Dos 5 per åldersgrupp’ tabs, respectively.
The ’eligible population method’ was used in this case, as it would not be appropriate to consider the whole population when considering vaccination coverage within specific age groups.
Data is available on the number of individuals aged 65-69 that have received the fifth dose. We have not included it in the heatmap because data is not available across the 60-69 age category used in the heatmap.
Note about the heatmap: A white colouration indicates that no data is available for that age group.
Code used to produce plot: Script to produce heatmap.
Ongoing research projects
Below is a manually curated overview of projects focussed on vaccine research that are/were supported by major funding agencies in Sweden. As it is manually curated, the list may not be exhaustive. If you are aware of a project that is not listed here but ought to be, please get in touch with us. For a list of all research projects funded by major funding agencies in Sweden, see this section of the portal instead.
Publications
Below is a subset of preprints and published scientific journal articles related to vaccine research that involve at least one author affiliated with a Swedish university or research institute. If you would like for your publication to be displayed here, or feel that information about a publication requires correction, please get in touch with us. For a fuller list of all publications related to COVID-19 and SARS-CoV-2 that involve at least one author affiliated with a Swedish university or research institute, please see this section of the portal.
| Artikel | Publicerad |
|---|---|
|
Confidence in COVID-19 vaccine effectiveness and safety and its effect on vaccine uptake in Tanzania: A community-based cross-sectional study. Mtei M, Mboya IB, Mgongo M, Manongi R, Amour C, Bilakwate JS, Nyaki AY, Ngocho J, Jonas N, Farah A, Amour M, Kalolo A, Kengia JT, Tinuga F, Ngalesoni F, Bakari AH, Kirakoya FB, Araya A, Kapologwe NA, Msuya SE Hum Vaccin Immunother 19 (1) 2191576. DOI: 10.1080/21645515.2023.2191576 |
2023-12-31 |
|
SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants. Lindahl H, Chen P, Åberg M, Ljunggren HG, Buggert M, Aleman S, Smith CIE, Bergman P J Clin Immunol 1-8. DOI: 10.1007/s10875-023-01486-8 |
2023-04-14 |
|
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T: an EPICOVIDEHA survey. van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, Farina F, Besson C, Weinbergerová B, Van Praet J, Schönlein M, Lopez-Garcia A, Lamure S, Guidetti A, De Ramón-Sánchez C, Batinic J, Gavriilaki E, Tragiannidis A, Tisi MC, Plantefeve G, Petzer V, Ormazabal-Velez I, Marques de Almeida J, Marchetti M, Maertens JA, Machado M, Kulasekararaj AG, Hernández-Rivas JÁ, Gomes da Silva M, Fernández N, Espigado I, Drgona L, Dragonetti G, Metafuni E, Calbacho M, Blennow O, Wolf D, van Anrooij B, Nunes Rodrigues R, Nordlander A, Martín-González JA, Lievin R, Jiménez M, Grafe SK, Garcia-Sanz R, Córdoba R, Rahimli L, van Meerten T, Cornely OA, Pagano L Blood Adv. DOI: 10.1182/bloodadvances.2022009578 |
2023-04-14 |
|
Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey. Naveen R, Thakare DR, Kuwana M, Pauling JD, Day J, Joshi M, Parodis I, Sen P, Jagtap K, Nikiphorou E, Saha S, Agarwal V, Chatterjee T, Lilleker JB, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Tan AL, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Distler O, Chinoy H, COVAD Study Group , Aggarwal R, Gupta L, Agarwal V, Makol A Rheumatol Int 1-11. DOI: 10.1007/s00296-023-05310-9 |
2023-03-31 |
|
Vulval Aphthous Ulcers in Adolescents Following COVID-19 Vaccination - Analysis of an international case series. Rudolph A, Savage DR J Pediatr Adolesc Gynecol. DOI: 10.1016/j.jpag.2023.03.006 |
2023-03-17 |
|
Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study. Husby A, Gulseth HL, Hovi P, Hansen JV, Pihlström N, Gunnes N, Härkänen T, Dahl J, Karlstad Ø, Heliö T, Køber L, Ljung R, Hviid A BMJ Med 2 (1) e000373. DOI: 10.1136/bmjmed-2022-000373 |
2023-02-01 |
|
Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. Xu Y, Li H, Kirui B, Santosa A, Gisslén M, Leach S, Wettermark B, Vanfleteren LEGW, Nyberg F Vaccines 10 (12). DOI: 10.3390/vaccines10122074 |
2022-12-05 |
|
B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients. Asplund Högelin K, Ruffin N, Pin E, Hober S, Nilsson P, Starvaggi Cucuzza C, Khademi M, Olsson T, Piehl F, Al Nimer F Eur J Neurol 29 (11) 3317-3328. DOI: 10.1111/ene.15492 |
2022-11-00 |
|
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Lenart K, Hellgren F, Ols S, Yan X, Cagigi A, Cerveira RA, Winge I, Hanczak J, Mueller SO, Jasny E, Schwendt K, Rauch S, Petsch B, Loré K Mol Ther Methods Clin Dev. DOI: 10.1016/j.omtm.2022.10.001 |
2022-10-06 |
|
Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations. Laffan MA, Rees S, Yadavalli M, Ferstenberg LB, Kumar Shankar N, Medin J, Foskett N, Arnold M, Gomes da Silva H, Bhuyan P, Nord M Vaccine 40 (38) 5585-5593. DOI: 10.1016/j.vaccine.2022.08.007 |
2022-09-09 |
|
Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents. Obach D, Solastie A, Liedes O, Vara S, Krzyżewska-Dudek E, Brinkmann L, Haveri A, Hammer CC, Dub T, Meri S, Freitag TL, Lyytikäinen O, Melin M Immun Inflamm Dis 10 (9) e679. DOI: 10.1002/iid3.679 |
2022-09-00 |
|
COVID-19 clinical outcomes and DMT of MS patients and population-based controls. Longinetti E, Bower H, McKay KA, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Piehl F, Frisell T Ann Clin Transl Neurol 9 (9) 1449-1458. DOI: 10.1002/acn3.51646 |
2022-09-00 |
|
Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines. Bell E, Brassel S, Oliver E, Schirrmacher H, Arnetorp S, Berg K, Darroch-Thompson D, Pohja-Hutchison P, Mungall B, Carroll S, Postma M, Steuten L Vaccines 10 (8). DOI: 10.3390/vaccines10081320 |
2022-08-15 |
|
Ethnic, racial and regional inequalities in access to COVID-19 vaccine, testing and hospitalization: Implications for eradication of the pandemic. Ahlberg BM, Bradby H Front Sociol 7 809090. DOI: 10.3389/fsoc.2022.809090 |
2022-08-09 |
|
Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021-2022: A Naturalistic Case-Control Study in Sweden. Spreco A, Dahlström Ö, Jöud A, Nordvall D, Fagerström C, Blomqvist E, Gustafsson F, Hinkula J, Schön T, Timpka T Vaccines 10 (8) 1273. DOI: 10.3390/vaccines10081273 |
2022-08-07 |
|
COVID vaccination in older adults. Hägg S, Religa D Nat Microbiol 7 (8) 1106-1107. DOI: 10.1038/s41564-022-01166-0 |
2022-08-00 |
|
VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. Salmanton-García J, Stewart FA, Heringer S, Koniordou M, Álvarez-Barco E, Argyropoulos CD, Themistocleous SC, Valle-Simón P, Spivak O, Součková L, Merakou C, Amélia Mendonça M, Joanna Davis R, Maria Azzini A, Askling HH, Vene S, Van Damme P, Steinbach A, Shiamakkides G, Seidel D, Olesen OF, Noula E, Macken A, Luís C, Leckler J, Launay O, Isitt C, Hellemans M, Frías-Iniesta J, Di Marzo R, Carcas AJ, Boustras G, Borobia AM, Barta I, Albus K, Akova M, Ochando J, Cohen-Kandli M, Jane Cox R, Husa P, Jancoriene L, Mallon P, Marques L, Mellinghoff SC, Nauclér P, Tacconelli E, Tóth K, Zaoutis TE, Zeitlinger M, Cornely OA, Pana ZD, VACCELERATE consortium Vaccine 40 (31) 4090-4097. DOI: 10.1016/j.vaccine.2022.05.022 |
2022-07-29 |
|
Macrotroponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection. Bularga A, Oskoui E, Fujisawa T, Jenks S, Sutherland R, Apple FS, Hammarsten O, Mills NL Clin Chem 68 (8) 1015-1019. DOI: 10.1093/clinchem/hvac100 |
2022-07-27 |
|
COVID-19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic Inflammatory Myopathies. Gil-Vila A, Naveen R, Selva-O'Callaghan A, Sen P, Nune A, Gaur PS, Gonzalez RA, Lilleker JB, Joshi M, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, COVAD Study Group Muscle Nerve. DOI: 10.1002/mus.27681 |
2022-07-23 |
|
Intrapulmonary Bronchopulmonary Anastomoses in Severe COVID-19-related Acute Respiratory Failure. Bodmer J, Levin A, Westöö C, van der Have O, Peruzzi N, Tran-Lundmark K, Abman SH, Galambos C Am J Respir Crit Care Med. DOI: 10.1164/rccm.202205-0922LE |
2022-07-20 |
|
Compliance with Health Recommendations and Vaccine Hesitancy During the COVID Pandemic in Nine Countries. Lansford JE, Rothenberg WA, Yotanyamaneewong S, Alampay LP, Al-Hassan SM, Bacchini D, Bornstein MH, Chang L, Deater-Deckard K, Di Giunta L, Dodge KA, Gurdal S, Liu Q, Long Q, Morgenstern G, Oburu P, Pastorelli C, Skinner AT, Sorbring E, Tapanya S, Steinberg L, Uribe Tirado LM Prev Sci. DOI: 10.1007/s11121-022-01399-9 |
2022-07-20 |
|
The effect of herd immunity thresholds on willingness to vaccinate. Andersson PA, Tinghög G, Västfjäll D Humanit Soc Sci Commun 9 (1) 243. DOI: 10.1057/s41599-022-01257-7 |
2022-07-18 |
|
Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer. Soto-Perez-de-Celis E, Mislang AR, Hernández-Favela CG, Russo C, Colloca G, Williams GR, O'Hanlon S, Cooper L, O'Donovan A, Audisio RA, Cheung KL, Gironés-Sarrió R, Stauder R, Jaklitsch M, Cairo C, Gil LA, Alam M, Sattar S, Kantilal K, Loh KP, Lichtman SM, Brain E, Wildiers H, Kanesvaran R, Battisti NML J Geriatr Oncol. DOI: 10.1016/j.jgo.2022.07.005 |
2022-07-15 |
|
Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study. Santosa A, Franzén S, Nåtman J, Wettermark B, Parmryd I, Nyberg F Sci Rep 12 (1) 12047. DOI: 10.1038/s41598-022-16357-2 |
2022-07-14 |
|
Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden. Nordström P, Ballin M, Nordström A Lancet Reg Health Eur 100466. DOI: 10.1016/j.lanepe.2022.100466 |
2022-07-13 |
|
mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells. Bevers S, Kooijmans SAA, Van de Velde E, Evers MJW, Seghers S, Gitz-Francois JJJM, van Kronenburg NCH, Fens MHAM, Mastrobattista E, Hassler L, Sork H, Lehto T, Ahmed KE, El Andaloussi S, Fiedler K, Breckpot K, Maes M, Van Hoorick D, Bastogne T, Schiffelers RM, De Koker S Mol Ther. DOI: 10.1016/j.ymthe.2022.07.007 |
2022-07-12 |
|
Willingness to Accept the COVID-19 Vaccine and Related Factors among Indian Adults: A Cross-Sectional Study. Parthasarathi A, Puvvada RK, Shankar M, Siddaiah JB, Ganguly K, Upadhyay S, Mahesh PA Vaccines 10 (7). DOI: 10.3390/vaccines10071095 |
2022-07-08 |
|
Vaccine Safety Surveillance Using Routinely Collected Healthcare Data-An Empirical Evaluation of Epidemiological Designs. Schuemie MJ, Arshad F, Pratt N, Nyberg F, Alshammari TM, Hripcsak G, Ryan P, Prieto-Alhambra D, Lai LYH, Li X, Fortin S, Minty E, Suchard MA Front Pharmacol 13 893484. DOI: 10.3389/fphar.2022.893484 |
2022-07-06 |
|
Scandinavian Nurses' Use of Social Media during the COVID-19 Pandemic-A Berger and Luckman Inspired Analysis of a Qualitative Interview Study. Glasdam S, Jacobsen FF, Hybholt L, Stjernswärd S Healthcare (Basel) 10 (7). DOI: 10.3390/healthcare10071254 |
2022-07-05 |
|
Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, Castilla J, Nielsen KF, Hansen CH, Emborg HD, Nardone A, Derrough T, Valenciano M, Nunes B, Monge S, VEBIS-Lot4 working group Euro Surveill 27 (30). DOI: 10.2807/1560-7917.ES.2022.27.30.2200551 |
2022-07-00 |
|
Integrating the CARD (Comfort Ask Relax Distract) system in a mass vaccination clinic to improve the experience of individuals during COVID-19 vaccination: a pre-post implementation study. Tetui M, Grindrod K, Waite N, VanderDoes J, Taddio A Hum Vaccin Immunother 2089500. DOI: 10.1080/21645515.2022.2089500 |
2022-06-20 |
|
Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines. Padín-González E, Lancaster P, Bottini M, Gasco P, Tran L, Fadeel B, Wilkins T, Monopoli MP Front Bioeng Biotechnol 10 882363. DOI: 10.3389/fbioe.2022.882363 |
2022-06-07 |
|
Resilience and post-traumatic growth in the transition to motherhood during the COVID-19 pandemic: A qualitative exploratory study. Thomson G, Cook J, Nowland R, Donnellan WJ, Topalidou A, Jackson L, Fallon V Scand J Caring Sci. DOI: 10.1111/scs.13087 |
2022-05-27 |
|
Intention to get COVID-19 vaccination and its associated predictors: A cross-sectional study among the general public in Algeria. Lounis M, Abdelhadi S, Rais MA, Bencherit D, Sallam M Vacunas. DOI: 10.1016/j.vacun.2022.04.003 |
2022-05-13 |
|
Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants. Gattinger P, Kratzer B, Tulaeva I, Niespodziana K, Ohradanova-Repic A, Gebetsberger L, Borochova K, Garner-Spitzer E, Trapin D, Hofer G, Keller W, Baumgartner I, Tancevski I, Khaitov M, Karaulov A, Stockinger H, Wiedermann U, Pickl WF, Valenta R Allergy. DOI: 10.1111/all.15305 |
2022-03-31 |
|
Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design. Lai LY, Arshad F, Areia C, Alshammari TM, Alghoul H, Casajust P, Li X, Dawoud D, Nyberg F, Pratt N, Hripcsak G, Suchard MA, Prieto-Alhambra D, Ryan P, Schuemie MJ Front Pharmacol 13 837632. DOI: 10.3389/fphar.2022.837632 |
2022-03-22 |
|
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic haematopoietic stem cell transplantation. Einarsdottir S, Martner A, Nicklasson M, Wiktorin HG, Arabpour M, Törnell A, Vaht K, Waldenström J, Ringlander J, Bergström T, Brune M, Hellstrand K, Ljungman P, Lagging M Haematologica. DOI: 10.3324/haematol.2021.280494 |
2022-03-03 |
|
High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters? Xu X, Vesterbacka J, Aleman S, Nowak P, COVAXID Study Group AIDS 36 (3) 479-481. DOI: 10.1097/QAD.0000000000003135 |
2022-03-01 |
|
Short-term improvement of mental health after a COVID-19 vaccination Chourpiliadis C, Lovik A, Kähler AK, Valdimarsdóttir UA, Frans EM, Nyberg F, Sullivan PF, Fang F . DOI: 10.1101/2022.02.22.22271327 |
2022-02-27 |
|
Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Aldén M, Olofsson Falla F, Yang D, Barghouth M, Luan C, Rasmussen M, De Marinis Y CIMB 44 (3) 1115-1126. DOI: 10.3390/cimb44030073 |
2022-02-25 |
|
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, Christ W, Sakharkar M, Ackerman ME, Klingström J, Forsell MNE, Walker LM Science eabn2688. DOI: 10.1126/science.abn2688 |
2022-02-10 |
|
Status of Planned and Ongoing Paediatric Trials Investigating COVID-19 Vaccines: A Cross-Sectional Study of Paediatric Clinical Trials Planned in Agreed PIPs and/or Registered in Clinical Trial Databases. Christiansen H, Thirstrup S, Hallgreen CE Ther Innov Regul Sci. DOI: 10.1007/s43441-021-00356-y |
2022-02-07 |
|
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden Nordström P, Ballin M, Nordström A Lancet. DOI: 10.1016/s0140-6736(22)00089-7 |
2022-02-00 |
|
T cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial. Blixt L, Wullimann D, Aleman S, Lundin J, Chen P, Gao Y, Cuapio A, Akber M, Lange J, Rivera-Ballesteros O, Buggert M, Ljunggren H, Hansson L, Österborg A Haematologica. DOI: 10.3324/haematol.2021.280300 |
2022-01-20 |
|
Novel universal SARS-CoV DNA vaccine inducing neutralizing antibodies to huCoV-19/WH01, Beta, Delta and Omicron variants and T cells to Bat-CoV Appelberg KS, Ahlen G, Nikoyan N, Yan J, Weber S, Larsson O, Höglund U, Aleman S, Weber F, Perlhamre E, Apro J, Gidlund EK, Tuvesson O, Cadossi M, Salati S, Tegel H, Hober S, Frelin L, mirazimi a, Sallberg M Research Square. DOI: 10.21203/rs.3.rs-1276351/v1 |
2022-01-20 |
|
Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study. Magnusson K, Skyrud KD, Suren P, Greve-Isdahl M, Størdal K, Kristoffersen DT, Telle K BMJ 376 e066809. DOI: 10.1136/bmj-2021-066809 |
2022-01-17 |
|
Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2. Bahnan W, Wrighton S, Sundwall M, Bläckberg A, Larsson O, Höglund U, Khakzad H, Godzwon M, Walle M, Elder E, Strand AS, Happonen L, André O, Ahnlide JK, Hellmark T, Wendel-Hansen V, Wallin RP, Malmstöm J, Malmström L, Ohlin M, Rasmussen M, Nordenfelt P Front Immunol 12 808932. DOI: 10.3389/fimmu.2021.808932 |
2022-01-14 |
|
Integrated epi-econ assessment of vaccination. Boppart T, Harmenberg K, Krusell P, Olsson J J Econ Dyn Control 104308. DOI: 10.1016/j.jedc.2022.104308 |
2022-01-13 |
|
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals Healy K, Pin E, Chen P, Söderdahl G, Nowak P, Mielke S, Hansson L, Bergman P, Smith CIE, Ljungman P, Valentini D, Blennow O, Österborg A, Gabarrini G, Al-Manei K, Alkharaan H, Sobkowiak MJ, Yousef J, Mravinacova S, Cuapio A, Xu X, Akber M, Loré K, Hellström C, Muschiol S, Bogdanovic G, Buggert M, Ljunggren HG, Hober S, Nilsson P, Aleman S, Sällberg Chen M Med (N Y). DOI: 10.1016/j.medj.2022.01.001 |
2022-01-00 |
|
Disease severity related to VOC dominance in unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden Wahlström E, Bruce D, Bennet Bark AM, Walther S, Hanberger H, Strålin K . DOI: 10.1101/2021.12.23.21268040 |
2021-12-27 |
|
Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season. Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S, Eckermann T, Godderis L, Martínez Gómez X, Godard E, Soler M, Yousefi M, Salamanca de la Cueva I, Nwoji U Infect Dis Ther. DOI: 10.1007/s40121-021-00571-y |
2021-12-27 |
|
SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population. Elgendy MO, El-Gendy AO, Alzarea AI, Mahmoud S, Alqahtani SS, Fahmy AM, El-Seedi HR, Sayed AM, Alatawi AD, Abdelrahim MEA, Alanazi AS Vaccines 10 (1). DOI: 10.3390/vaccines10010018 |
2021-12-24 |
|
Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity. Rahman M, Irmler M, Keshavan S, Introna M, Beckers J, Palmberg L, Johanson G, Ganguly K, Upadhyay S Viruses 13 (12). DOI: 10.3390/v13122537 |
2021-12-17 |
|
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination Kaku CI, Champney ER, Normark J, Johnson CE, Ahlm C, Sakharkar M, Ackerman ME, Forsell MNE, Walker LM MedRxiv. DOI: 10.1101/2021.12.13.21267598 |
2021-12-14 |
|
The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Ljung R, Sundström A, Grünewald M, Backman C, Feltelius N, Gedeborg R, Zethelius B Ups J Med Sci 126. DOI: 10.48101/ujms.v126.8136 |
2021-12-10 |
|
Increasing risk of breakthrough COVID-19 in outbreaks with high attack rates in European long-term care facilities, July to October 2021 Suetens C, Kinross P, Gallego Berciano P, Arroyo Nebreda V, Hassan E, Calba C, Fernandes E, Peralta-Santos A, Casaca P, Shodu N, Dequeker S, Kontopidou F, Pappa L, Kacelnik O, Børseth AW, O’Connor L, Garvey P, Liausedienė R, Valintelienė R, Ernst C, Mossong J, Štefkovičová M, Prostináková Z, Danielsen AC, Mougkou A, Lamb F, Cenciarelli O, Monnet DL, Plachouras D Euro Surveill 26 (49). DOI: 10.2807/1560-7917.es.2021.26.49.2101070 |
2021-12-09 |
|
To be or not to be vaccinated against COVID-19 - The adolescents' perspective - A mixed-methods study in Sweden. Nilsson S, Mattson J, Berghammer M, Brorsson AL, Forsner M, Jenholt Nolbris M, Kull I, Lindholm Olinder A, Ragnarsson S, Rullander AC, Rydström LL, Andréia Garcia de Avila M, Olaya-Contreras P Vaccine X 9 100117. DOI: 10.1016/j.jvacx.2021.100117 |
2021-12-00 |
|
A population-based dataset concerning predictors of willingness to get a COVID-19 vaccine in Iran. Pakpour AH, Yahaghi R, Ahmadizade S, Fotuhi R, Taherkhani E, Ranjbaran M, Buchali Z, Lin CY, Griffiths MD, Broström A Data Brief 39 107459. DOI: 10.1016/j.dib.2021.107459 |
2021-12-00 |
|
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Smith CIE, Wullimann D, Vesterbacka J, Lindgren G, Blixt L, Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini D, Norlin A, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K, Chen MS, Buggert M, Ljunggren H, Ljungman P, Aleman S, COVAXID-collaborator group (shown separately) EBioMedicine 74 103705. DOI: 10.1016/j.ebiom.2021.103705 |
2021-11-29 |
|
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Sen P, Gupta L, Lilleker JB, Aggarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O'Callaghan AS, Nikiphorou E, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Cagnotto G, Nune A, Distler O, Chinoy H, Aggarwal V, Aggarwal R, COVAD Study Group Rheumatol Int. DOI: 10.1007/s00296-021-05046-4 |
2021-11-15 |
|
Utilization of health care services before and after media attention about fatal side effects of the AstraZeneca vaccine: a nation-wide register-based event study. Larsen VB, Grøsland M, Telle K, Magnusson K BMC Health Serv Res 21 (1) 1229. DOI: 10.1186/s12913-021-07233-2 |
2021-11-13 |
|
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy. Lockmer S, Uttervall K, Kashif M, Svärd C, Malmsten K, Fletcher-Torres E, Alici E, Lund J, Nahi H Am J Hematol 96 (11) E443-E446. DOI: 10.1002/ajh.26348 |
2021-11-01 |
|
Allergen Immunotherapy management during vaccinations: An international survey. Masieri S, Bachert C, Ojeda P, Kim CK, Carlo C, Giorgio C, Study Group on AIT & Vaccinations World Allergy Organ J 14 (11) 100601. DOI: 10.1016/j.waojou.2021.100601 |
2021-11-00 |
|
Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database. Kim MS, Jung SY, Ahn JG, Park SJ, Shoenfeld Y, Kronbichler A, Koyanagi A, Dragioti E, Tizaoui K, Hong SH, Jacob L, Salem JE, Yon DK, Lee SW, Ogino S, Kim H, Kim JH, Excler JL, Marks F, Clemens JD, Eisenhut M, Barnett Y, Butler L, Ilie CP, Shin EC, Il Shin J, Smith L J Med Virol. DOI: 10.1002/jmv.27424 |
2021-10-28 |
|
Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models. Gokumakulapalle M, Wang L, Mei YF Front Microbiol 12 698999. DOI: 10.3389/fmicb.2021.698999 |
2021-10-27 |
|
Structural Modeling on the Determinants of Effectiveness of SOPs Containing COVID-19 in Mass Gatherings. Basit A, Scholz M, Niazi AAK, Qazi TF, Shaukat MZ, Rao ZU, Mahmood A Front Psychol 12 755221. DOI: 10.3389/fpsyg.2021.755221 |
2021-10-27 |
|
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults Lanini S, Capone S, Antinori A, Milleri S, Nicastri E, Camerini R, Agrati C, Castilletti C, Mori F, Sacchi A, Matusali G, Gagliardini R, Ammendola V, Cimini E, Grazioli F, Scorzolini L, Napolitano F, Plazzi MM, Soriani M, De Luca A, Battella S, Sommella A, Contino AM, Barra F, Gentile M, Raggioli A, Shi Y, Girardi E, Maeurer M, Capobianchi MR, Vaia F, Piacentini M, Kroemer G, Vitelli A, Colloca S, Folgori A, Ippolito G, Ottou S, Vita S, Vergori A, D’Abramo A, Petrecchia A, Montaldo C, Scalise E, Grassi G, Casetti R, Bordoni V, Notari S, Colavita F, Meschi S, Lapa D, Bordi L, Murachelli S, Tambasco T, Grillo A, Masone E, Marchioni E, Bardhi D, Porzio O, Cocca F, Murachelli S, Turrini I, Malescio F, Ziviani L, Lawlor R, Poli F, Martire F, Zamboni D, Mazzaferri F Sci. Transl. Med.. DOI: 10.1126/scitranslmed.abj1996 |
2021-10-26 |
|
Lack of Trust, Insufficient knowledge and Risk denial; an in-depth Understanding of Health workers Barriers to uptake of the Covid-19 vaccine at Iganga Hospital Eastern Uganda, and Mengo Hospital Kampala Uganda Muhamadi L, Edith N, James W, Tumwesigye NM, Museene SK, Mukakaarisa H, Peterson SS, Ekström AM . DOI: 10.1101/2021.10.13.21264920 |
2021-10-19 |
|
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W, Phillipson M, Nilsson P, Hober S, Blom K, Klingström J, Mangsbo S, Åberg M, Thålin C MedRxiv. DOI: 10.1101/2021.10.16.21264948 |
2021-10-19 |
|
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients. Melin J, Svensson MK, Albinsson B, Winqvist O, Pauksens K BMC Immunol 22 (1) 70. DOI: 10.1186/s12865-021-00458-0 |
2021-10-19 |
|
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Nordström P, Ballin M, Nordström A Lancet Reg Health Eur 100249. DOI: 10.1016/j.lanepe.2021.100249 |
2021-10-18 |
|
Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age and time period and are affected by the pandemic Nyberg F, Lindh M, Vanfleteren LEGW, Hammar N, Wettermark B, Sundström J, Santosa A, Kirui BK, Gisslén M MedRxiv. DOI: 10.1101/2021.10.04.21263507 |
2021-10-05 |
|
High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F Infect Dis (Lond) 1-6. DOI: 10.1080/23744235.2021.1982144 |
2021-09-29 |
|
Identification of Unique Peptides for SARS-CoV-2 Diagnostics and Vaccine Development by an In Silico Proteomics Approach Kesarwani V, Gupta R, Vetukuri RR, Kushwaha SK, Gandhi S Front Immunol 12. DOI: 10.3389/fimmu.2021.725240 |
2021-09-24 |
|
Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination. van de Munckhof A, Krzywicka K, Aguiar de Sousa D, Sánchez van Kammen M, Heldner MR, Jood K, Lindgren E, Tatlisumak T, Putaala J, Kremer Hovinga JA, Middeldorp S, Levi M, Arnold M, Ferro JM, Coutinho JM Eur J Neurol. DOI: 10.1111/ene.15113 |
2021-09-18 |
|
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination Normark J, Vikström L, Gwon YD, Persson IL, Edin A, Björsell T, Dernstedt A, Christ W, Tevell S, Evander M, Klingström J, Ahlm C, Forsell M N Engl J Med 385 (11) 1049-1051. DOI: 10.1056/nejmc2110716 |
2021-09-09 |
|
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. Seppälä E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O, Taxt AM, Watle SV, Meijerink H Euro Surveill 26 (35). DOI: 10.2807/1560-7917.ES.2021.26.35.2100793 |
2021-09-00 |
|
COVID-19 vaccine uptake among older people in relation to sociodemographic factors –cohort results from southern Sweden Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F, Björk J . DOI: 10.1101/2021.08.12.21261981 |
2021-08-13 |
|
Neutralization of VOCs including Delta one year post COVID-19 or vaccine Havervall S, Marking U, Gordon M, Ng H, Greilert-Norin N, Lindbo S, Blom K, Nilsson P, Phillipson M, Klingström J, Mangsbo S, Åberg M, Hober S, Thålin C MedRxiv. DOI: 10.1101/2021.08.12.21261951 |
2021-08-12 |
|
Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021. Mateo-Urdiales A, Del Manso M, Andrianou X, Spuri M, D'Ancona F, Filia A, Rota MC, Petrone D, Vescio MF, Riccardo F, Bella A, Pezzotti P, Fabiani M Vaccine 39 (34) 4788-4792. DOI: 10.1016/j.vaccine.2021.07.003 |
2021-08-09 |
|
Swedish Covid-19 Investigation for Future Insights - A Population Epidemiology Approach Using Register Linkage (SCIFI-PEARL). Nyberg F, Franzén S, Lindh M, Vanfleteren L, Hammar N, Wettermark B, Sundström J, Santosa A, Björck S, Gisslén M CLEP 13 649-659. DOI: 10.2147/CLEP.S312742 |
2021-07-30 |
|
Vaccine allergy: evidence to consider for COVID-19 vaccines. Nilsson L, Csuth Á, Storsaeter J, Garvey LH, Jenmalm MC Curr Opin Allergy Clin Immunol. DOI: 10.1097/ACI.0000000000000762 |
2021-06-04 |
|
DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice Szurgot I, Hanke L, Sheward DJ, Vidakovics LP, Murrell B, McInerney GM, Liljeström P Sci Rep 11 (1) 3125. DOI: 10.1038/s41598-021-82498-5 |
2021-02-04 |
|
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G Nat Commun 12 (1) 372. DOI: 10.1038/s41467-020-20653-8 |
2021-01-14 |
Other sources of information about COVID-19 vaccines
- General information about COVID-19 is available from The Swedish Health Agency.
- Information about COVID-19 vaccines is available from The Swedish Medical Products Agency.
- For health information connected to vaccination and tests by different Swedish regions, see regional information on 1177.
- Information about COVID-19 vaccine approval, rollout, and safety is available from The European Centre for Disease Prevention and Control (ECDC).
- Additional information about COVID-19 vaccines is available from the Centre for disease Control (CDC).
- Information and data visualisations related to the register-based large-scale national population study to monitor COVID-19 vaccination effectiveness and safety (RECOVAC) are presented in a separate dashboard on this Portal.